Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Cendakimab in Healthy Chinese Participants
NCT05638282Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Cendakimab with Placebo (2 arms). Primary endpoints: Maximum Observed Serum Concentration at Day 105, Area Under the Serum Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration at Day 105 and 1 more. Started Feb 2023; status: completed.
02
Drugs
cendakimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05638282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638282.